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Abstract Tocolysis is an important treatment in the
improvement of outcome in preterm labor and preterm
birth, provided that its use follows clear evidence-based
recommendations. In this expert opinion, the most recent
evidence about efficacy and side effects of different toco-
lytics is being reviewed and evidence-based recommen-
dation about diagnosis and treatment of preterm labor is
given. Further aspects such as progesterone administration
or antibiotic treatment for the prevention of preterm birth
are included. Our review demonstrates that an individual-
ized choice of different tocolytics and additional treatments
is necessary to improve short- and long-term neonatal
outcome in preterm labor and preterm birth.
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Introduction
This Expert Opinion Letter gives current evidence-based
recommendations on indication and selection of tocolytics.
The incidence of preterm birth, i.e., delivery before
37 weeks of gestation, in Switzerland lies around 7.5 %,
with 1 % occurring before 32 weeks of gestation [1]. This
puts Switzerland in the middle of the pack compared with
the rate of prematurity in Europe as a whole (5.5–11.4 %).
Prematurity accounts for about 75 % of perinatal mortality
and for about 50 % of long-term morbidity [2].
It is often difficult to identify the pregnant women at
high risk for preterm birth in time to prevent it. Approxi-
mately 90 % of women presenting with contractions will
not deliver within the next 7 days and about 75 % of them
will reach term without tocolysis or any other therapies [3].
Many pregnant women with preterm contractions are thus
‘‘over-treated’’. The goal must therefore be the identification
of the women who are truly at risk of going on to preterm
birth to prevent unnecessary and costly interventions.
Only the timely recognition of an impending preterm
birth allows for a risk-specific management with stabil-
ization of the pregnant woman and transfer to a specialized
perinatology unit. About a third of all preterm births are
medically indicated (preeclampsia, intrauterine growth
retardation, etc.). Approximately 40–50 % are the results
of preterm labor and a further 30 % occur after preterm
rupture of membranes before 37 weeks of gestation. The
recommendations presented concern predominantly the
latter two groups.
The management of threatened preterm birth consists of:
• Diagnostic procedures to evaluate the risk and plan
appropriate therapy.
• Initiation of tocolysis.
• Administration of corticosteroids to promote fetal lung
maturity [4].
• Possible administration of antibiotics.
• Transfer to a specialized perinatal center.
Diagnosis
The following diagnostic procedures are mandatory:
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1. Medical history: Identification of women at high risk,
i.e., with multiple gestations, uterine malformations,
fibroids, or a history of previous preterm birth, second
trimester pregnancy loss, induced abortions, and
repeated uterine curettage, conization, or other cervical
procedures. Careful documentation of complications in
the current pregnancy as well as the actual complaints
at presentation such as lower abdominal cramping,
back pain, and vaginal discharge [5, 6].
2. CTG: Assessment of fetal wellbeing and uterine activity.
3. Abdominal ultrasound examination: Position, weight,
morphology of the fetus, position and morphology of
the placenta, amount of amniotic fluid, Doppler
evaluation of placental and fetal circulation.
4. Speculum Exam: Evaluation of possible bleeding, amni-
otic fluid leak, prolapse of fetal membranes. To obtain
material for cultures. Fetal fibronectin test and tests for
presence of amniotic fluid are optional (see below).
5. Endovaginal Sonography: Evaluation of cervical length,
evaluation/exclusion of placenta previa, and vasa previa.
6. Blood tests: CRP and leucocytes for exclusion of
amniotic fluid infection syndrome.
Transvaginal ultrasound is superior to digital examination
in the detection of impending premature birth [7–9]. In the
presence of preterm rupture of membranes, all vaginal
examinations (speculum or sonography) should be restricted
as much as possible and only conducted under strictly sterile
conditions [10, 11]. Digital examination should be avoided
before delivery is under way. If after history, speculum exam
and sonography there is still uncertainty as to the presence of
preterm rupture of membranes, immune-chromatological
tests (AmniSure, Actim Prom test) are recommended [12].
Indications for tocolysis (24 1 0–33 1 6 weeks
of gestation)
The use of tocolytics before 24 weeks of gestation can be
justified in individual cases (i.e., preoperatively with cer-
vical cerclage). The use of tocolytics during external ver-
sion for breech position, for the intrauterine reanimation or
for the delivery of the baby during cesarian section will not
be addressed in this Expert Opinion Letter.
For initiation of tocolysis one or more of the following
criteria must be met:
• Preterm spontaneous labor (CTG[4 uterine contractions
in 20 min, or 6 in 60 min) and one of the following:
– Shortening of the functional length of the cervix to
B25 mm, or shortening of the cervix by[5 mm (by
transvaginal sonography) over the course of 2 h.
– Positive fibronectin test (optional).
– Symptomatic placenta previa/low lying placenta
with vaginal bleeding.
– Cervical dilatation of [2 cm and \5 cm.
• Preterm spontaneous rupture of membranes prior to
34 weeks of gestation without signs of chorioamnioni-
tis (optional indication, no general recommendation).
In unclear situations, the measuring of fetal fibronectin
may provide further guidance on how to proceed. The risk
of preterm birth rises to 50 % with gestational age of
B32 weeks, cervical length of B15 mm, and a positive
fibronectin test. If the fibronectin test is negative and cer-
vical length is 15 mm, the risk of delivery within the next
7 days drops to B1 % [13–15]. With a cervical length of
C25 mm and a negative fibronectin test at 24 weeks of
gestation, the risk of preterm birth is minimal based on a
negative predictive value of [95 % [16]. Other biochem-
ical tests including IGFBP-1 (insulin growth factor binding
protein-1) and PAMG-1 (placental alpha microglobulin-1)
have similar predictive values in the diagnosis of ‘‘true’’
preterm labor, and can be used clinically.
Goal of tocolysis
The primary goal of a tocolysis is the prevention of a
preterm delivery before the end of the 37th week of ges-
tation. As this goal is often not obtainable, tocolysis should
aim for prolonging the pregnancy to 34 weeks of gestation,
or at the very least by 48 h to allow for one-time admin-
istration of Betamethasone (Celestone), 2 9 12 mg i.m.
24 h apart, which can reduce perinatal mortality and
morbidity by as much as 50 % [17]. A further goal of
tocolysis is making it possible to transfer the fetus in utero
to a specialized perinatal center which further significantly
reduces perinatal mortality and morbidity. Conversely, the
fetus should not sustain any damage from remaining in a
hostile intrauterine environment (i.e., due to infection!);
under these circumstances, a prolongation of the pregnancy
through tocolysis would not be appropriate.
Contraindications to tocolysis [18]
Maternal indications for
ending the pregnancy
Fetal indications for ending the
pregnancy
Sepsis Pathological CTG
Severe preeclampsia Premature placental separation (relative
contraindication)
Maternal hemodynamic
instability
Chorioamnionitis
Pulmonary edema Intrauterine fetal demise or fetal
malformations not compatible with
life
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Acute tocolysis
Tocolytics manage to delay delivery by 24 to max. 7 days.
However, so far no reduction of the rate of preterm birth
before 32, resp., 37 weeks of gestation, or of neonatal
morbidity (respiratory distress syndrome or intraventricular
hemorrhage) and/or perinatal mortality could be docu-
mented in randomized placebo-controlled trials for the
various beta-sympathomimetics, oxytocin receptor agonists
or prostaglandin synthesis inhibitors [19]. This lack of
demonstrable benefit for the neonate can be explained
though by methodological weaknesses in the RCTs pub-
lished thus far [20]. The positive effect on morbidity and
mortality of the transfer to a specialized perinatal center
made possible by tocolysis and the induction of lung
maturity is not taken into account either. According to the
current state of knowledge, all the listed tocolytics are
equally efficacious in regards to suppression of labor and
their selection should be on the basis of absolute and rel-
ative contraindications for their use is a given patient.
Calcium antagonists appear to have a better neonatal out-
come than beta-sympathomimetics, though long-term out-
come data are lacking [21]. Beta-sympathomimetics and
oxytocin receptor antagonists are approved in Switzerland
for tocolysis, whereas the use of calcium antagonists for
tocolysis is an off-label indication, which has to be dis-
closed and explained to the patient before starting them.
The need for a change in treatment (rescue therapy, non-
response to a tocolytics), the general attitude in a specific
institution, or economic criteria may all influence the
choice of tocolytic [22]. The lack of evidence justifies a
restricted use of tocolytics. A combination of different
tocolytics should generally be avoided because such com-
bination may potentiate severe adverse effects [22, 23].
Tocolytics with promising data
Beta-Sympathomimetics
Intravenously administered beta-sympathomimetics
(hexoprenaline, fenoterole) have a documented tocolytic
effect, though when compared to placebo or oxytocin
receptor antagonists, they clearly have a higher rate of
maternal adverse effects based on their mechanism of
action (palpitations in 48 %, tremor in 39 %, headache in
23 %, chest pain in 10 % of patients). In combination with
corticosteroids and excessive i.v. fluid administration
(especially in the presence of infection) they also have a
higher risk (1:425) of pulmonary edema [19, 20]. By
administering tocolysis in bolus form or through fluid
restriction, the rate of maternal adverse effects can be
reduced [24]. Fetal adverse effects include transient
tachycardia or hypoglycemia when beta-sympathomimetics
were administered within 2 days of delivery [22]. It is
therefore recommended to use them for a restricted dura-
tion and dosage under strict volume control [25]. There is
no documented efficacy of beta-sympathomimetics when
given orally.
Specific contraindications for beta-sympathomimetics
are:
– Cardiac disease including arrhythmias.
– Thyrotoxicosis.
– Severe preeclampsia.
– Uncontrolled diabetes mellitus (cave; exacerbation of
hyperglycemia).
– Pulmonary edema.
– Multiple gestation (relative contraindication).
– Severe anemia.
Oxytocin receptor antagonists
Oxytocin receptor antagonists have comparable tocolytic
efficacy to beta-sympathomimetics, but with markedly
fewer maternal adverse effects [26, 27, 28] and have an
optimal risk–benefit profile. Palpitations occur in 2 %,
tachycardia in 6 %, and headache in 10 % of patients.
Severe adverse effects have not been reported for use of
oxytocin receptor antagonists alone [22]. For this reason
they are considered, together with calcium antagonists, the
first line tocolytic by many international specialty societies.
In high-risk situations (elevated risk for pulmonary edema,
in multiple gestations, with polyhydramnios, cardiac or
pulmonary disease, diabetes mellitus I, persistent contrac-
tions, and/or tachycardia with hexoprenaline) atosiban
should be the first line tocolytic. Atosiban is administered
i.v. in a loading dose of 6.75 lg over 1 min, followed by
3 h of 18 mg per hour and thereafter as a maintenance dose
of 6 mg/h for 45 h. The total treatment time should not
exceed 48 h. The maximal dose for a single course should
not exceed 330 mg. The price is significantly higher than
for other tocolytics.
Calcium antagonists
Calcium antagonists have, compared to beta-sympat-
homimetics, a better risk–benefit profile, i.e., equal effi-
cacy in regards to prolongation of pregnancy with a low
rate of maternal and fetal adverse effects. For this reason
they are recommended by various international specialty
societies, together with oxytocin receptor antagonists, as
first line tocolytics [20, 29, 30]. It is also important to
notice that calcium antagonists are the only tocolytic that
can be given orally. This, however, has only been
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documented with nifedipin (but not for other calcium
antagonists) in comparison with other tocolytics [31].
Compared to beta-sympathomimetics, nifedipin improves
neonatal morbidity (respiratory distress syndrome, intra-
ventricular hemorrhage, necrotizing enterocolitis) and has
fewer maternal adverse effects [32]. Based on the lack of
long-term outcome data and because of the question
regarding the optimal dosage there is still a need for
further and larger scale studies. Adverse effects include
lowering of blood pressure (cave: orthostatic vertigo) and
headaches. Severe adverse reactions in the form of pul-
monary edema have been observed, especially in twin
pregnancies.
Current recommendations call for nifedipin slow release
(Adalat CR) with a loading dose of 30–40 mg p.o. (10 mg
every 10–15 min) during the first hour, then 60 mg a day
up to a maximal dose of 120–150 mg per day [33]. An
alternative regimen consists of nifedipin 10 mg to chew,
combined with 20 mg nifedipin slow release (Adalat CR)
for a rapid saturation; after 60 min a maintenance dose of
60 mg nifedipin low release is given and 30 mg nifedipin
slow release kept in reserve [34]. A maintenance dose of
90 mg nifedipin slow release (alternating 30 mg and 60 mg
every 12 h) also was well tolerated [35, 36]. Nifedipin can
be combined with high dose magnesium sulfate (i.e., with
preeclampsia) [37].
Specific contraindications for calcium antagonists are
[38]:
– Cardiac disease including arrhythmias.
– Arterial hypertension.
– Pulmonary edema.
– Multiple gestation (relative contraindication).
– Intrauterine growth retardation (\5th percentile).
Tocolytics with limited data, despite documentation
of tocolytic effect
Prostaglandin synthesis inhibitors
Prostaglandin synthesis inhibitors (especially indometha-
cin) have been used for tocolysis. In randomized studies a
significantly better tocolytic effect compared to placebo
and at least comparable with that of other tocolytics was
documented. However, the subject numbers are too small
to give a clear recommendation [39, 40]. Possible fetal
adverse effects include impaired renal function (with sub-
sequent oligohydramnios) and the constriction of the duc-
tus arteriosus; they should therefore not be used for longer
than 48 h. Recommended are 100 mg as a loading dose
followed by 50 mg every 6–8 h.
Specific contraindications to indomethacin are:
– Gestational age [32 weeks.
– Current or past gastric ulcer.
– Hypertension.
– Allergy to NSAIDs.
– Severe intrauterine growth retardation.
– Oligohydramnios.
Nitric oxide donor drugs
Even though NO-donors (transdermal with NitroTTS
patch) were able to show in an RTC a significant reduction
in neonatal morbidity with preterm birth before 28 weeks
of gestation, there is not yet sufficient evidence of the
efficacy of using them as tocolytics outside of a study
setting [41]. The most common adverse effect is therapy
resistant headache.
Tocolytics without demonstrated tocolytic effect
Magnesium sulfate
There is no definitively proven effect of magnesium sulfate
as a tocolytic. The effects of magnesium on tocolysis have
yielded contradictory results in clinical studies [42, 43].
Nevertheless, magnesium is, unlike in Europe, the most
commonly used tocolytic in the USA. The usual initial
dose of 6 g i.v. over 20 min is generally followed by a
maintenance dose of 3–4 g/h, a dose somewhat higher than
the one commonly used for preeclampsia [44]. If used at
all, MgSO4 should be limited to 48 h. The neuroprotective
effect for the child, long suspected based on epidemio-
logical data, is now also documented in a randomized study
[45]. Due to remaining open questions, the use of magne-
sium sulfate as a neuroprotective agent can at this point not
be recommended generally. If used, it should be adminis-
tered during the last 24 h before delivery. The only well-
documented indication for intravenous magnesium sulfate
administration to pregnant women remains the prophylaxis
and treatment of seizures in preeclampsia and eclampsia.
Regulatory approval of tocolytics
In Switzerland, the beta-sympathomimetic hexoprenaline
(Gynipral) and the oxytocin antagonist atosiban (Tracto-
cile) are approved for the treatment of preterm labor, while
this is not the case for calcium antagonists, prostaglandin
synthesis inhibitors, and nitrous oxide donors. If these are to
be used, the patient has to be fully informed about their ‘‘off-
label’’ use and possible alternative treatments [46].
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Long-term tocolysis
So far there is no clear evidence for the benefits of an oral
long-term tocolysis with beta-sympathomimetics, oxytocin
receptor agonists or calcium antagonists [47–50]. Routine
long-term tocolysis can therefore not be recommended and
should only be used in selected individual cases (i.e., with
symptomatic placenta previa and early gestational age). In
general practice, we frequently encounter individual cases
where a continuation of tocolysis appears to have resulted
in the prevention of preterm delivery. It is likely that the
assumed benefits for the newborn in those instances cannot
be statistically captured due to the small number of cases.
Further measures
Bed rest
A randomized study published in 1994 showed no effect of
strict bed rest on the rate of preterm birth [51]. Because of
the documented adverse effects associated with strict bed
rest, such as an increased risk of thrombo-embolic events,
more frequent depression or a feeling of isolation, there is
generally no indication for ordering strict bed rest [52, 53].
Prescription of modified bed rest and sick leave is
acceptable.
Bryophyllum
A tocolytic effect of Bryophyllum pinnatum has been
shown in vitro and in several observational reports or ret-
rospective studies. Data from two prospective controlled
studies (RCT) conducted according to the requirements of
the regulatory agencies are pending. Further studies will be
necessary to increase the evidence for its use as a tocolytic
[54–56].
Antibiotics
There is no evidence that the administration of antibiotics
to women with preterm labor and intact membranes lowers
the rate of preterm birth [57]. Follow-up studies at 7 years
have shown an increased risk of cerebral palsy in the same
patient collective [58]. In selected cases, such as with
preterm labor in the presence of a smear positive for group
B streptococci, antibiotic is indicated even with intact
membranes [59]. In women with preterm rupture of
membranes before 34 weeks gestation, on the other hand,
the administration of antibiotics (erythromycin, amoxicil-
lin, clindamycin) results in a prolongation of the pregnancy
and a reduction of neonatal morbidity [60].
Progesterone
According to a meta-analysis in 2012, the prophylactic
administration of vaginal progesterone (100–200 mg per
day) to asymptomatic women with a singleton pregnancy
and a cervical length of\25 mm, as well as to women with
a prior preterm birth, reduced the rate of preterm delivery
by 50 % and favorably influenced perinatal morbidity and
mortality (less RDS, less LBW). Progesterone did not work
in twin or higher grade multiple gestations [61–66]. About
the use of progesterone for the treatment of preterm labor,
there is so far insufficient evidence-based information.
Conflict of interest The authors report no conflict of interest.
References
1. Bundesamt fu¨r Statistik aktuell (2010) Gesundheit der Neuge-
borenen 2008 Fru¨hgeburten, Mehrlingsschwangerschaften und
Wachstumsretardierung. wwwadminch
2. McCormick MC (1985) The contribution of low birth weight to
infant mortality and childhood morbidity. N Engl J Med
312(2):82–90. doi:10.1056/NEJM198501103120204
3. Ness A, Visintine J, Ricci E, Berghella V (2007) Does knowledge of
cervical length and fetal fibronectin affect management of women
with threatened preterm labor? A randomized trial. Am J Obstet
Gynecol 197(4):426 e1–426 e7. doi:S0002-9378(07)00884-8
4. Surbek D, D G, Irion O, Nelle M, Ho¨sli I (2009) Lung-
enreifungsinduktion bei drohender Fru¨hgeburt: Standardindika-
tionen und Dosierung. SGGG Expertenbrief No 34
5. Goffinet F (2005) Primary predictors of preterm labour. BJOG
112(Suppl 1):38–47. doi:10.1111/j.1471-0528.2005.00583.x
6. Moreau C, Kaminski M, Ancel PY, Bouyer J, Escande B, Thiriez
G et al (2005) Previous induced abortions and the risk of very
preterm delivery: results of the EPIPAGE study. BJOG
112(4):430–437. doi:10.1111/j.1471-0528.2004.00478.x
7. Gomez R, Galasso M, Romero R, Mazor M, Sorokin Y, Gon-
calves L et al (1994) Ultrasonographic examination of the uterine
cervix is better than cervical digital examination as a predictor of
the likelihood of premature delivery in patients with preterm
labor and intact membranes. Am J Obstet Gynecol 171(4):956–
964. doi:0002-9378(94)90014-0
8. Crane JM, Van den Hof M, Armson BA, Liston R (1997)
Transvaginal ultrasound in the prediction of preterm delivery:
singleton and twin gestations. Obstet Gynecol 90(3):357–363.
doi:S0029-7844(97)00277-9
9. Sonek JD, Iams JD, Blumenfeld M, Johnson F, Landon M, Gabbe
S (1990) Measurement of cervical length in pregnancy: com-
parison between vaginal ultrasonography and digital examina-
tion. Obstet Gynecol 76(2):172–175
10. Schutte MF, Treffers PE, Kloosterman GJ, Soepatmi S (1983)
Management of premature rupture of membranes: the risk of
vaginal examination to the infant. Am J Obstet Gynecol 146(4):
395–400
11. Munson LA, Graham A, Koos BJ, Valenzuela GJ (1985) Is there
a need for digital examination in patients with spontaneous rup-
ture of the membranes? Am J Obstet Gynecol 153(5):562–563.
doi:0002-9378(85)90474-0
12. Birkenmaier A, Ries JJ, Kuhle J, Burki N, Lapaire O, Hosli I
(2012) Placental alpha-microglobulin-1 to detect uncertain
Arch Gynecol Obstet (2014) 289:903–909 907
123
rupture of membranes in a European cohort of pregnancies. Arch
Gynecol Obstet. doi:10.1007/s00404-011-1895-9
13. Hassan SS, Romero R, Berry SM, Dang K, Blackwell SC,
Treadwell MC et al (2000) Patients with an ultrasonographic
cervical length \ or = 15 mm have nearly a 50% risk of early
spontaneous preterm delivery. Am J Obstet Gynecol
182(6):1458–1467. doi:S0002-9378(00)81396-4
14. ACOG Practice Bulletin (2001) Assessment of risk factors for
preterm birth. Clinical management guidelines for obstetrician–
gynecologists. Number 31, October 2001. (Replaces Technical
Bulletin number 206, June 1995; Committee Opinion number
172, May 1996; Committee Opinion number 187, September
1997; Committee Opinion number 198, February 1998; and
Committee Opinion number 251, January 2001). Obstet Gynecol
98(4):709–716
15. Kagan KO, To M, Tsoi E, Nicolaides KH (2006) Preterm birth:
the value of sonographic measurement of cervical length. BJOG
113(Suppl 3):52–56. doi:10.1111/j.1471-0528.2006.01124.x
16. Chandiramani M, Di Renzo GC, Gottschalk E, Helmer H, Hen-
rich W, Hoesli I et al (2011) Fetal fibronectin as a predictor of
spontaneous preterm birth: a European perspective. J Matern
Fetal Neonatal Med 24(2):330–336. doi:10.3109/14767058.2010.
496879
17. Crowley P (2000) Prophylactic corticosteroids for preterm birth.
Cochrane Database Syst Rev (2):CD000065. 10.1002/14651858.
CD000065
18. American College of O, Gynecologists, Committee on Practice
B-O (2012) ACOG practice bulletin no. 127: management of
preterm labor. Obstet Gynecol 119(6):1308–1317. doi:10.1097/
AOG.0b013e31825af2f0
19. Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A (1999) Toco-
lytics for preterm labor: a systematic review. Obstet Gynecol
94(5 Pt 2):869–877
20. RCOG (2011) Tocolysis for women in preterm labour guidelines
for the management of spontaneous preterm labour Green top
clinical guideline No 1(B)
21. Conde-Agudelo A, Romero R, Kusanovic JP (2011) Nifedipine in
the management of preterm labor: a systematic review and met-
aanalysis. Am J Obstet Gynecol 204(2):134 e1–134 e20. doi:10.
1016/j.ajog.2010.11.038
22. DGGG (2010) Leitlinien Medikamento¨se Wehenhemmung bei
drohender Fru¨hgeburt
23. de Heus R, Mol BW, Erwich JJ, van Geijn HP, Gyselaers WJ,
Hanssens M et al (2009) Adverse drug reactions to tocolytic
treatment for preterm labour: prospective cohort study. BMJ
338:b744
24. Herzog S, Cunze T, Martin M, Osmers R, Gleiter C, Kuhn W
(1999) Pulsatile vs. continuous parenteral tocolysis: comparison
of side effects. Eur J Obstet Gynecol Reprod Biol 85(2):199–204.
doi:S0301211599000305
25. Anotayanonth S, Subhedar NV, Garner P, Neilson JP, Harigopal
S (2004) Betamimetics for inhibiting preterm labour. Cochrane
Database Syst Rev. (4):CD004352. doi: 10.1002/14651858.
CD004352.pub2
26. The Worldwide Atosiban versus Beta-agonists Study Group
(2001) Effectiveness and safety of the oxytocin antagonist atos-
iban versus beta-adrenergic agonists in the treatment of preterm
labour. BJOG 108(2):133–142
27. Coomarasamy A, Knox EM, Gee H, Khan KS (2002) Oxytocin
antagonists for tocolysis in preterm labour–a systematic review.
Med Sci Monit 8(11):RA268–RA273
28. Romero R, Sibai BM, Sanchez-Ramos L, Valenzuela GJ, Veille
JC, Tabor B et al (2000) An oxytocin receptor antagonist (atos-
iban) in the treatment of preterm labor: a randomized, double-
blind, placebo-controlled trial with tocolytic rescue. Am J Obstet
Gynecol 182(5):1173–1183
29. Di Renzo GC, Roura LC (2006) Guidelines for the management
of spontaneous preterm labor. J Perinat Med 34(5):359–366.
doi:10.1515/JPM.2006.073
30. Tsatsaris V, Papatsonis D, Goffinet F, Dekker G, Carbonne B
(2001) Tocolysis with nifedipine or beta-adrenergic agonists: a
meta-analysis. Obstet Gynecol 97(5 Pt 2):840–847. doi:S0029784
400012126
31. King JF, Flenady VJ, Papatsonis DN, Dekker GA, Carbonne B
(2003) Calcium channel blockers for inhibiting preterm labour.
Cochrane Database Syst Rev. (1):CD002255. doi: 10.1002/
14651858.CD002255
32. Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ
(2012) Tocolytic therapy for preterm delivery: systematic review
and network meta-analysis. BMJ 345:e6226
33. Papatsonis DN, Van Geijn HP, Ader HJ, Lange FM, Bleker OP,
Dekker GA (1997) Nifedipine and ritodrine in the management of
preterm labor: a randomized multicenter trial. Obstet Gynecol
90(2):230–234. doi:10.1016/S0029-7844(97)00182-8
34. Zimmermann R (2012) Handbuch Geburtshilfe
35. Silberschmidt AL, Kuhn-Velten WN, Juon AM, Zimmermann R,
von Mandach U (2008) Nifedipine concentration in maternal and
umbilical cord blood after nifedipine gastrointestinal therapeutic
system for tocolysis. BJOG 115(4):480–485. doi:10.1111/j.1471-
0528.2007.01630.x
36. Juon AM, Kuhn-Velten WN, Burkhardt T, Krahenmann F,
Zimmermann R, von Mandach U (2008) Nifedipine gastrointes-
tinal therapeutic system (GITS) as an alternative to slow-release
for tocolysis–tolerance and pharmacokinetic profile. Eur J Obstet
Gynecol Reprod Biol 140(1):27–32. doi:10.1016/j.ejogrb.2008.
02.003
37. Magee LA, Miremadi S, Li J, Cheng C, Ensom MH, Carleton B
et al (2005) Therapy with both magnesium sulfate and nifedipine
does not increase the risk of serious magnesium-related maternal
side effects in women with preeclampsia. Am J Obstet Gynecol
193(1):153–163. doi:10.1016/j.ajog.2004.11.059
38. sapp.info (2010) Monographie Nifedipin. www sappinfo Mo-
nographie Nifedipin
39. Haas DM, Imperiale TF, Kirkpatrick PR, Klein RW, Zollinger
TW, Golichowski AM (2009) Tocolytic therapy: a meta-analysis
and decision analysis. Obstet Gynecol 113(3):585–594. doi:10.
1097/AOG.0b013e318199924a
40. King J, Flenady V, Cole S, Thornton S (2005) Cyclo-oxygenase
(COX) inhibitors for treating preterm labour. Cochrane Database
Syst Rev (2):CD001992. doi:10.1002/14651858.CD001992.pub2
41. Smith GN, Walker MC, Ohlsson A, O’Brien K, Windrim R
(2007) Randomized double-blind placebo-controlled trial of
transdermal nitroglycerin for preterm labor. Am J Obstet Gynecol
196(1):37 e1–37.e8. doi:10.1016/j.ajog.2006.10.868
42. Crowther CA, Hiller JE, Doyle LW (2002) Magnesium sulphate
for preventing preterm birth in threatened preterm labour.
Cochrane Database Syst Rev (4):CD001060. doi: 10.1002/
14651858.CD001060
43. Grimes DA, Nanda K (2006) Magnesium sulfate tocolysis: time
to quit. Obstet Gynecol 108(4):986–989. doi:10.1097/01.AOG.
0000236445.18265.93
44. Jeyabalan A, Caritis SN (2002) Pharmacologic inhibition of
preterm labor. Clin Obstet Gynecol 45(1):99–113
45. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer
BM et al (2008) A randomized, controlled trial of magnesium
sulfate for the prevention of cerebral palsy. N Engl J Med
359(9):895–905. doi:10.1056/NEJMoa0801187
46. SGGG (2007) Expertenbrief No. 23 ‘‘Off Label Use’’ von Arz-
neimitteln in der Gyna¨kologie und Geburtshilfe
47. Lyell DJ, Pullen KM, Mannan J, Chitkara U, Druzin ML,
Caughey AB et al (2008) Maintenance nifedipine tocolysis
compared with placebo: a randomized controlled trial. Obstet
908 Arch Gynecol Obstet (2014) 289:903–909
123
Gynecol 112(6):1221–1226. doi:10.1097/AOG.0b013e31818d
8386
48. Dodd JM, Crowther CA, Dare MR, Middleton P (2006) Oral
betamimetics for maintenance therapy after threatened preterm
labour. Cochrane Database Syst Rev (1):CD003927. doi: 10.
1002/14651858.CD003927.pub2
49. Whitworth M, Quenby S (2008) Prophylactic oral betamimetics
for preventing preterm labour in singleton pregnancies. Cochrane
Database Syst Rev (1):CD006395. doi: 10.1002/14651858.
CD006395.pub2
50. Papatsonis D, Flenady V, Liley H (2009) Maintenance therapy
with oxytocin antagonists for inhibiting preterm birth after
threatened preterm labour. Cochrane Database Syst Rev
(1):CD005938. doi: 10.1002/14651858.CD005938.pub2
51. Sosa C, Althabe F, Belizan J, Bergel E (2004) Bed rest in sin-
gleton pregnancies for preventing preterm birth. Cochrane
Database Syst Rev (1):CD003581. doi: 10.1002/14651858.
CD003581.pub2
52. Heaman M, Gupton A (1998) Perceptions of bed rest by women
with high-risk pregnancies: a comparison between home and
hospital. Birth 25(4):252–258
53. Heaman MI, Blanchard JF, Gupton AL, Moffatt ME, Currie RF
(2005) Risk factors for spontaneous preterm birth among
Aboriginal and non-Aboriginal women in Manitoba. Paediatr
Perinat Epidemiol 19(3):181–193. doi:10.1111/j.1365-3016.2005.
00644.x
54. Wachter R, Brenneisen R, Hamburger M, Mennet M, Schnelle M,
Worel AM et al (2011) Leaf press juice from Bryophyllum
pinnatum (Lamarck) Oken induces myometrial relaxation. Phy-
tomedicine. doi:10.1016/j.phymed.2011.06.032
55. Plangger N, Rist L, Zimmermann R, von Mandach U (2006)
Intravenous tocolysis with Bryophyllum pinnatum is better tol-
erated than beta-agonist application. Eur J Obstet Gynecol Re-
prod Biol 124(2):168–172. doi:10.1016/j.ejogrb.2005.05.013
56. Gwehenberger B, Rist L, Huch R, von Mandach U (2004) Effect
of Bryophyllum pinnatum versus fenoterol on uterine contrac-
tility. Eur J Obstet Gynecol Reprod Biol 113(2):164–171. doi:10.
1016/S0301-2115(03)00370-1
57. King J, Flenady V (2002) Prophylactic antibiotics for inhibiting
preterm labour with intact membranes. Cochrane Database Syst
Rev (4):CD000246. doi: 10.1002/14651858.CD000246
58. Kenyon S, Pike K, Jones DR, Brocklehurst P, Marlow N, Salt A
et al (2008) Childhood outcomes after prescription of antibiotics
to pregnant women with spontaneous preterm labour: 7-year
follow-up of the ORACLE II trial. Lancet 372(9646):1319–1327.
doi:10.1016/S0140-6736(08)
59. Verani JR, McGee L, Schrag SJ (2010) Prevention of perinatal
group B streptococcal disease—revised guidelines from CDC.
MMWR Recomm Rep 59(RR-10):1–36
60. Kenyon SL, Taylor DJ, Tarnow-Mordi W, ORACLE Collabora-
tive Group (2001) Broad-spectrum antibiotics for preterm, pre-
labour rupture of fetal membranes: the ORACLE I randomised
trial. Lancet 357(9261):979–988. doi:S0140673600042331
61. Dodd JM, Flenady V, Cincotta R, Crowther CA (2006) Prenatal
administration of progesterone for preventing preterm birth.
Cochrane Database Syst Rev (1):CD004947. doi: 10.1002/
14651858.CD004947.pub2
62. Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK,
Khandelwal M et al (2011) Vaginal progesterone reduces the rate
of preterm birth in women with a sonographic short cervix: a
multicenter, randomized, double-blind, placebo-controlled trial.
Ultrasound Obstet Gynecol 38(1):18–31. doi:10.1002/uog.9017
63. Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O’Brien
JM, Cetingoz E et al (2012) Vaginal progesterone in women with
an asymptomatic sonographic short cervix in the midtrimester
decreases preterm delivery and neonatal morbidity: a systematic
review and metaanalysis of individual patient data. Am J Obstet
Gynecol 206(2):124 e1–124 e19. doi:10.1016/j.ajog.2011.12.003
64. Meis PJ, Aleman A (2004) Progesterone treatment to prevent
preterm birth. Drugs 64(21):2463–2474
65. Sanchez-Ramos L, Kaunitz AM, Delke I (2005) Progestational
agents to prevent preterm birth: a meta-analysis of randomized
controlled trials. Obstet Gynecol 105(2):273–279. doi:10.1097/
01.AOG.0000150559.59531.b2
66. Likis FE, Edwards DR, Andrews JC, Woodworth AL, Jerome
RN, Fonnesbeck CJ et al (2012) Progestogens for preterm birth
prevention: a systematic review and meta-analysis. Obstet
Gynecol 120(4):897–907. doi:10.1097/AOG.0b013e3182699a15
Arch Gynecol Obstet (2014) 289:903–909 909
123
